P. Kongsaeree et al. / Tetrahedron: Asymmetry 12 (2001) 1913–1922
1921
2.9, 2.4 Hz, 1H), 4.83 (ddd, J 6.8, 5.9, 5.4 Hz, 1H), 6.04
(d, J 2.4 Hz, 1H), 6.49 (d, J 2.9 Hz, 1H), 7.15 (broad
peak, 1H), whose spectroscopic data are identical in all
respects to those reported.8e
from the Nation Center for Genetic Engineering and
Biotechnology (BIOTEC)/Nation Science and Technol-
ogy Development Agency (NSTDA).
4.7.4. (2R,3S)-Tetrahydro-4-methylene-5-oxo-2-n-pen-
tyl-3-furancarboxylic acid [(+)-methylenolactocin], (+)-
References
1%a. Obtained as
a
white crystalline solid
1. For reviews on the occurrence, biological properties, and
synthesis a-methylene-g-butyrolactones, see: (a) Cavillto,
C. J.; Haskell, T. H. J. Chem. Soc. 1946, 68, 2332–2334;
(b) Yoshioka, H.; Mabry, T. J.; Timmermann, B. N.
Sesquiterpene Lactones; University of Tokyo Press:
Tokyo, 1973; (c) Grieco, P.A. Synthesis 1975, 67–82; (d)
Hoffmann, H. M. R.; Rabe, J. Angew. Chem., Int. Ed.
Engl. 1985, 24, 94–110; (e) Petragnani, N.; Ferraz, H. M.
C.; Silva, G. V. L. Synthesis, 1986, 157–183.
2. (a) Park, B. K.; Nakagawa, M.; Hirota, A.; Nakayama,
M. Agric. Biol. Chem. 1987, 51, 3443; (b) Park, B. K.;
Nakagawa, M.; Hirota, A.; Nakayama, M. J. Antibiot.
1988, 44, 751–758; (c) Nakayama, M.; Nakagawa, S.;
Boku, T.; Hirota, A.; Shima, S.; Nakanishi, O.; Yamada,
Y. Jpn. Kokai Tokkyo Koho 1989, 1 (16), 776; Chem.
Abstr. 1990, 112, 34404f.
3. Enantiomeric syntheses of methylenolactocin: (a) de
Azevedo, M. B. M.; Murta, M. M.; Greene, A. E. J. Org.
Chem. 1992, 57, 4567–4569; (b) Takahata, H.; Uchida,
Y.; Momose, T. J. Org. Chem. 1995, 60, 5628–5633; (c)
Vaupel, A.; Knochel, P. Tetrahedron Lett. 1995, 36,
231–232; (d) Mawson, S. D.; Weavers, R. T. Tetrahedron
1995, 51, 11257–11270; (e) Zhu, G.; Lu, X. Tetrahedron
Asymmetry 1995, 6, 885–892; (f) Drioli, S.; Felluga, F.;
Forzata, C.; Nitti, P.; Pitacco, G. Chem. Commun. 1996,
1289–1290; (g) Chandrasekharam, M.; Liu, R. S. J. Org.
Chem. 1998, 63, 9122–9124; (h) Masaki, Y.; Arasaki, H.;
Itoh, A. Tetrahedron Lett. 1999, 40, 4829–4832.
4. Asahina, Y.; Yanagita, M.; Sakurai, Y. Ber. Chem. 1937,
70B, 227–235.
5. (a) Zopf, W. Liebigs Ann. Chem. 1902, 324, 39–78; (b)
Asahina, Y.; Asano, M. J. Pharm. Sci. Jpn. 1927, 539,
1–17; (c) Asahina, Y.; Yanagita, M. Chem. Ber. 1936,
69B, 120–125.
6. Enantiomeric syntheses of protolichesterinic acid: (a)
Murta, M. M.; de Azevedo, M. B. M.; Greene, A. E. J.
Org. Chem. 1993, 58, 7537–7541; (b) Martin, T.;
Rodriguez, C. M.; Martin, V. S. J. Org. Chem. 1996, 61,
6450–6453.
7. (a) Be´rdy, J. Handbook of Antibiotic Compounds; CRC
Press: Boca Raton, FL, 1982; Vol. IX and references
cited therein; (b) Cavallito, C. J.; Fruehuauf, M. D.;
Bailey, J. N. J. Am. Chem. Soc. 1948, 70, 3724–3726; (c)
Shibata, S.; Miura, Y.; Sugimura, H.; Toyoizumi, Y. J.
Pharm. Soc. Jpn. 1948, 68, 300–303; Chem. Abstr. 1951,
45, 6691i; (d) Fujikawa, F.; Hitosa, Y.; Yamaoka, M.;
Fujiwara, Y.; Nakazawa, S.; Omatsu, T.; Toyoda, T. J.
Org. Chem. 1953, 73, 135–138; Chem. Abstr. 1954, 48,
230a; (e) Borkawski, B.; Wozniak, W.; Gertig, H.; Wer-
akso, B. Diss. Pharm. 1964, 16, 189–194; Chem. Abstr.
1965, 62, 1995b; (f) Sticker, O. Pharm. Acta Helv. 1965,
40, 183–195; Chem. Abstr. 1965, 63, 8778d; (g) Sticker, O.
Pharm. Acta Helv. 1965, 40, 385–394; Chem. Abstr. 1965,
63, 12026c; (h) Hirayama, T.; Fujikawa, F.; Kasahara,
(EtOAc/hexane): mp 82–83°C (lit.3d mp 82–83°C
(EtOAc/hexane)); [h]3D2=+7.4 (c, 0.33, MeOH), [h]3D0=
+16.6 (c, 0.33, CHCl3); (lit.3e [h]D25=+6.8 (c, 0.51,
MeOH) whose spectroscopic data are identical in all
respects to those reported.8e
4.7.5. (2R,3S)-Tetrahydro-4-methylene-5-oxo-2-n-unde-
cyl-3-furancarboxylic acid [(+)-nephrosterinic acid],
(+)-1%b. Obtained as a white crystalline solid (EtOAc/
hexane): mp 86–88°C; [h]3D2=+7.5 (c, 0.43, MeOH),
[h]D32=+13.0 (c, 0.66, CHCl3); (lit.4 [h]TD=+10.8) whose
spectroscopic data are identical in all respects to those
reported.8e
4.7.6. (2R,3S)-Tetrahydro-4-methylene-5-oxo-2-n-tride-
cyl-3-furancarboxylic acid [(+)-protolichesterinic acid],
(+)-1%c. Obtained as a white crystalline solid (EtOAc/
hexane): mp 101–103°C (lit.6a mp 103–105°C (EtOAc/
hexane)); [h]D31=+10.0 (c, 0.24, CH3OH), [h]3D2=+11.2
(c, 0.50, CHCl3); (lit.6b [h]D25=+14.2 (c, 0.95, CHCl3))
whose spectroscopic data are identical in all respects to
those reported.8e
4.7.7. (11S)-Tetrahydro-4%-carbomenthoxy-5%-n-pentyl-
2%-furanone -3%-spiro -11 -9,10 -dihydro -9,10 -ethanoan-
thracenes, (−)-8. Using the typical procedure described
in Section 4.7.1, capronaldehyde (0.28 mL, 2.27 mmol)
was reacted with menthyl methyl itaconate–anthracene
adduct, (−)-6 (1.0011 g, 1.89 mmol) to give enan-
tiomeric spiro–lactoness, (4%R,5%R,11R)-tetrahydro-4%-
carbomenthoxy-5%-n-pentyl-2%-furanone-3%-spiro-11-9,10-
dihydro-9,10-ethanoanthracenes, (−)-8 (0.346 g, 34%).
Compound (4%R,5%R,11R)-8: White crystals; mp 205–
206°C (from hexane); [h]3D1=−179.5 (c, 0.40, CHCl3).
IR (KBr-pellet), wmax 2989, 2931, 2872, 1783, 1722,
1460, 1371, 1176, 1137 cm−1. 1H NMR (400 MHz,
CDCl3): l 0.88 (t, J 6.9 Hz, 3H), 0.92 (d, J 7.0 Hz, 3H),
0.96 (d, J 7.0 Hz, 3H), 0.99 (d, J 6.5 Hz, 3H), 1.00–1.81
(m, 15H), 1.98, 2.13, 4.40 (ABX system, J 12.4, 3.0, 2.4
Hz, 3H), 2.01 (m, 1H), 2.25 (d, J 4.9 Hz, 1H), 2.38 (m,
1H), 4.33 (m, 1H), 4.80 (s, 1H), 4.84 (ddd, J 10.8, 4.9,
4.4 Hz, 1H), 7.05–7.35 (m, 8H). 13C NMR (100 MHz,
CDCl3): l 13.9, 15.9, 21.1, 22.1, 22.4, 22.7, 25.1, 25.6,
31.2, 31.4, 31.5, 34.1, 40.6, 41.2, 43.8, 46.4, 46.7, 50.7,
58.1, 76.4, 77.0, 122.5, 123.8, 124.5, 125.85, 125.93,
126.1, 126.7, 127.5, 140.0, 140.9, 142.5, 143.1, 169.6,
176.8. m/z (ESITOF-MS) 529.3317 (M+H)+, calcd for
C30H36O4 529.3318.
Acknowledgements
This work was supported by post-graduate study grant
(to P.M.) and a senior Fellowship Award (to Y.T.)